First published · Last updated
Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial
A multicenter, single-arm phase 2 trial testing chemotherapy plus camrelizumab for fertility preservation in FIGO stage IB1 cervical cancer is reported as a journal article. The supplied source fields include no trial results, sample sizes, locations, or outcomes.
Categories: science-and-space, public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 6/10
- Geographic reach
- 3/10
- Global importance
- 2/10
- Impact magnitude
- 2/10
- Positivity
- 5/10
- Urgency
- 1/10
Why it matters
This trial pertains to fertility-preserving treatment research for early-stage cervical cancer.

